Sectors

  • What GoGold’s Record Quarter Doesn’t Say Up Front

    What GoGold’s Record Quarter Doesn’t Say Up Front

    GoGold’s operating cash flow hit a record $26.3 million last quarter. Net income fell to $10.9 million from $16.4 million the quarter before. All-in sustaining costs per ounce very nearly doubled. The company reported all three numbers in the same release, and led with the first one. GoGold Reports Record Operating Cash Flow of $26.3…

    read more

  • QuantumCore Closes C$4.69M Financing With US Investor, Plus Another Small-Cap Tech Move

    QuantumCore Closes C$4.69M Financing With US Investor, Plus Another Small-Cap Tech Move

    QuantumCore doesn’t build quantum computers. It builds the cryogenic chips that let quantum computers actually talk to the outside world, and a US investor just backed that bet with enough new capital to upsize the round mid-raise. Across the country, a fintech company that has spent years turning a struggling China lending business into something…

    read more

  • X-Energy’s Revenue Jumps 154% as Stock Gains 10% on Q2 Results

    X-Energy’s Revenue Jumps 154% as Stock Gains 10% on Q2 Results

    X-Energy told investors last week that a definitive fuel contract with Centrus Energy would de-risk its reactor pipeline. This week the company reported the numbers behind that claim: revenue and grant income of $54.6 million, up 154% from a year earlier, and a stock that jumped roughly 10% on the news. The same report showed…

    read more

  • OmniAb Jumps 13% on Eli Lilly Ion Channel Collaboration

    OmniAb Jumps 13% on Eli Lilly Ion Channel Collaboration

    OmniAb landed a partner with deep pockets on Monday. Acurx Pharmaceuticals landed something smaller but just as telling: a brand name regulators are willing to put on a drug label. Neither event is an approval. Both moved the stock like one. OmniAb Jumps 13% on Eli Lilly Collaboration Worth Up to $370 Million OmniAb (Nasdaq:…

    read more

  • Strategy Faces MSCI Index Exclusion Again, This Time Asset-Neutral

    Strategy Faces MSCI Index Exclusion Again, This Time Asset-Neutral

    Strategy has been here before. In October 2025, MSCI proposed excluding bitcoin treasury companies from its indexes and the market wiped out $190 billion in leveraged positions inside 48 hours before the index provider backed down in January. This month MSCI came back with a different rule that reaches the same companies anyway. MSCI’s New…

    read more

  • Three Juniors Report Results: Namibia, New Brunswick, Nevada

    Three Juniors Report Results: Namibia, New Brunswick, Nevada

    A single drill hole running 831 metres is longer than most projects’ entire resource pit. This week one company reported exactly that, and the grades got better as the hole went deeper, not worse. Two smaller stories landed the same week, one a brand new discovery on the other side of the world, the other…

    read more

  • Securitize Stock Falls 20% After First Earnings Report as Public Company

    Securitize Stock Falls 20% After First Earnings Report as Public Company

    A tokenization company just posted its first earnings report as a public company, and Wall Street didn’t like the math. Shares fell more than 20% in a single after-hours session, erasing a solid gain from earlier the same day. The same week, U.S. regulators quietly cleared the path for one of the world’s largest asset…

    read more

  • Fobi AI Resumes Trading After 21-Month Cease Trade Order

    Fobi AI Resumes Trading After 21-Month Cease Trade Order

    Fobi AI’s stock hasn’t traded on the TSXV since November 2024. On August 13, it starts again. The company used the same round of announcements to disclose a working capital deficiency, a board that doesn’t meet audit committee requirements, and a shareholder meeting that’s more than two years overdue. Trading Resumes August 13 After a…

    read more

  • Tenax Therapeutics Stock Craters 90% After Phase 3 Trial Misses Primary Endpoint

    Tenax Therapeutics Stock Craters 90% After Phase 3 Trial Misses Primary Endpoint

    Tenax Therapeutics closed at $13.45 on Friday. It opened Monday at $1.77. In between, the company’s only Phase 3 trial reported a treatment difference of 3.5 meters on its primary endpoint, a result so far from significance that seven Wall Street analysts cut their price targets by roughly 90% apiece within a single trading day.…

    read more

  • First Phosphate Elevates ADR Listing to Nasdaq Global Market as Two Clean Energy Stocks Diverge on Fresh Disclosures

    First Phosphate Elevates ADR Listing to Nasdaq Global Market as Two Clean Energy Stocks Diverge on Fresh Disclosures

    A Quebec phosphate developer just added a major U.S. exchange to its growing list of listings, the fourth market where its shares now trade. A thermal energy storage company just shrank its share count for the third time in seven months to keep its stock above a dollar. And a Texas solar manufacturer beat Wall…

    read more